(NYSE: HLN) Haleon's forecast annual revenue growth rate of 3.34% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Haleon's revenue in 2024 is $14,306,329,113.On average, 3 Wall Street analysts forecast HLN's revenue for 2024 to be $133,148,453,448,780, with the lowest HLN revenue forecast at $131,710,048,525,142, and the highest HLN revenue forecast at $134,539,152,564,007. On average, 3 Wall Street analysts forecast HLN's revenue for 2025 to be $139,047,379,162,563, with the lowest HLN revenue forecast at $137,496,247,796,170, and the highest HLN revenue forecast at $140,324,520,723,390.
In 2026, HLN is forecast to generate $145,950,186,162,940 in revenue, with the lowest revenue forecast at $145,023,533,617,295 and the highest revenue forecast at $146,836,003,423,105.